Navigation Links
Reportlinker Adds Renal Disease Treatments: Products and Therapies
Date:12/2/2009

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Renal Disease Treatments: Products and Therapies

http://www.reportlinker.com/p0166824/Renal-Disease-Treatments-Products-and-Therapies.html

Forecasts for the U.S. market in products and services, providing data for 2008 and estimates for 2009, and projections for the market and compound annual growth rates (CAGRs) from 2009 to 2014

Focus on pharmaceutical products, dialysis therapies, and surgical procedures in the U.S. market for renal failure treatment

Breakdown of the dialysis equipment market by type and manufacturer, and the dialysis services market by provider

Detailed company profiles

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOAL AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 4

DISCLAIMER 4

Chapter-2: SUMMARY

SUMMARY 5

SUMMARY TABLE THE U.S. MARKET FOR RENAL FAILURE TREATMENT, THROUGH 2014 ($ MILLIONS) 6

SUMMARY FIGURE U.S. MARKET FOR RENAL FAILURE TREATMENT, 1996-2014 ($ MILLIONS) 7

Chapter-3: OVERVIEW

KIDNEY FUNCTION 8

KIDNEY DISEASE 9

TABLE 1 DISEASES LEADING TO RENAL FAILURE 10

DETECTING KIDNEY DISEASE 10

TYPICAL TESTS 10

PATIENT POPULATIONS 11

TABLE 2 ESTIMATED ARF, CKD, AND ESRD POPULATIONS, INCLUDING TRANSPLANT RECIPIENTS AND ROUTINE DIALYSIS PATIENTS, 1996-2009 12

FIGURE 1 ESTIMATED ARF, CKD, AND ESRD POPULATIONS, INCLUDING TRANSPLANT RECIPIENTS AND ROUTINE DIALYSIS PATIENTS, 1996-2009 12

HOSPITALIZATIONS WITH RENAL FAILURE LISTED AS A DIAGNOSIS 12

FIGURE 2 AGE-SPECIFIC HOSPITALIZATION RATES* FOR KIDNEY DISEASE,** BY AGE GROUP -- NATIONAL HOSPITAL DISCHARGE SURVEY, UNITED STATES, 1980-2005 13

FIGURE 3 AGE-ADJUSTED HOSPITALIZATION RATES FOR KIDNEY DISEASE BY TYPE, 1980-2005 14

TABLE 3 NUMBER OF HOSPITALIZATIONS AND AGE-ADJUSTED HOSPITALIZATION RATES FOR KIDNEY DISEASE, BY SEX AND YEAR, NATIONAL HOSPITAL DISCHARGE SURVEY, 1980-2005 15

FIGURE 4 NUMBER OF HOSPITALIZATIONS FOR KIDNEY DISEASE, BY SEX AND YEAR, NATIONAL HOSPITAL DISCHARGE SURVEY, 1980-2005 16

WHO PAYS THE COSTS OF KIDNEY DISEASE? 16

WHAT MEDICARE COVERS 17

MEDICARE'S ESRD PROGRAM 18

Breakdown of ESRD Population by Payer 19

Chapter-4: ACUTE KIDNEY FAILURE

INCIDENCE OF ACUTE KIDNEY FAILURE 20

CAUSES OF ACUTE KIDNEY FAILURE 21

PRERENAL FAILURE 21

RENAL DAMAGE 21

POSTRENAL FAILURE 22

ACUTE KIDNEY FAILURE TREATMENT 23

COSTS OF TREATING ACUTE RENAL FAILURE 23

TABLE 4 BREAKDOWN OF AVERAGE ARF TREATMENT COSTS, BY SUBCATEGORY OF CARE ($) 24

FIGURE 5 BREAKDOWN OF ARF TREATMENT COSTS, BY SUBCATEGORY OF CARE ($) 24

PHARMACEUTICALS 25

FUROSEMIDE 25

DOPAMINE 25

EPINEPHRINE 26

RENAL RELACEMENT THERAPY 26

RESEARCH SUGGESTS NO SUPERIORITY OF RRT MODES IN TREATING ARF 27

THE U.S. MARKET FOR TREATING ACUTE RENAL FAILURE 27

PHARMACEUTICALS IN ARF TREATMENT 28

RRT IN ARF TREATMENT 28

TABLE 5 U.S MARKET FOR ACUTE RENAL FAILURE TREATMENT, THROUGH 2014 ($ MILLION) 29

FIGURE 6 U.S. MARKET FOR ACUTE RENAL FAILURE TREATMENT, 1996-2014 ($ MILLION) 30

Chapter-5: CHRONIC KIDNEY FAILURE

INCIDENCE OF CHRONIC KIDNEY FAILURE 31

CAUSES OF CHRONIC KIDNEY FAILURE 31

TABLE 6 PRIMARY CAUSES OF KIDNEY FAILURE (% OF PATIENTS) 32

FIGURE 7 PRIMARY CAUSES OF KIDNEY FAILURE (% OF PATIENTS) 33

FIGURE 8 CKD PREDICTORS IN THE U.S. POPULATION AGED 20 AND OLDER 34

CKD STAGES 34

TABLE 7 STAGES OF CHRONIC KIDNEY DISEASE 35

STAGE 1 35

STAGE 2 35

STAGE 3 36

STAGE 4 36

STAGE 5 (ESRD) 36

NUMBER OF INDIVIDUALS WITH CKD 37

TABLE 8 PATIENTS WITH CKD AND AWARENESS OF THE DISEASE, BY STAGE, 2009 (NUMBER AND %) 37

FIGURE 9 PATIENTS WITH CKD AND AWARENESS OF THE DISEASE, BY STAGE 2009 (%) 37

CHARACTERISTICS OF THE CKD PATIENT POPULATION 38

TABLE 9 CKD PATIENT CHARACTERISTICS (COLUMN %) 38

TREATMENT GOALS 38

TABLE 10 ESRD TREATMENT, BY MODALITY (PERCENTAGE AND NUMBER OF PATIENTS) 40

FIGURE 10 ESRD TREATMENT, BY MODALITY (PERCENTAGE OF PATIENTS) 40

TABLE 11 DIALYSIS FOR ESRD, BY TREATMENT MODALITY, 2009 41

FIGURE 11 DIALYSIS FOR ESRD, BY TREATMENT MODALITY, 2009 (%) 41

COSTS OF CHRONIC KIDNEY DISEASE 41

TABLE 12 INPATIENT/OUTPATIENT AND PHYSICIAN /SUPPLIER NET COSTS FOR CKD ($, PER PATIENT PER MONTH, 2006) 42

TABLE 12 (CONTINUED) 43

FIGURE 12 PPPM EXPENDITURES FOR CKD PATIENTS, 1993-2006 (MEDICARE, MEDICARE/MEDICAID, MEDSTAT [EMPLOYER PAID INSURANCE]) 44

THE U.S. MARKET FOR TREATING CHRONIC KIDNEY FAILURE AND END-STAGE RENAL DISEASE 45

TABLE 13 THE U.S. MARKET FOR CKD/ESRD TREATMENT BY TYPE, 1996-2014 ($ MILLION) 46

FIGURE 13 THE U.S. MARKET FOR CHRONIC RENAL FAILURE TREATMENT BY TYPE, 1996-2014 ($ MILLION) 46

Chapter-6: PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT

TABLE 14 PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT BY TYPE AND MANUFACTURER 47

TABLE 14 (CONTINUED) 48

ANTIHYPERTENSIVES 48

ACE INHIBITORS 48

TABLE 15 COMMONLY PRESCRIBED ACE INHIBITORS: BRAND NAME, GENERIC NAME AND MANUFACTURER 49

ANGIOTENSIN RECEPTOR BLOCKERS 49

TABLE 16 COMMONLY PRESCRIBED ANGIOTENSIN RECEPTOR BLOCKERS BRAND NAME, GENERIC NAME AND MANUFACTURER 50

BETA-BLOCKERS 50

TABLE 17 COMMONLY PRESCRIBED BETA BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER 50

CALCIUM CHANNEL BLOCKERS 51

TABLE 18 COMMONLY PRESCRIBED CALCIUM CHANNEL BLOCKERS 51

DIRECT RENIN INHIBITORS 51

CHOLESTEROL MANAGEMENT MEDICATIONS 52

STATINS 52

TABLE 19 COMMONLY PRESCRIBED STATIN DRUGS 53

BILE ACID SEQUESTRANTS 53

TABLE 20 COMMONLY-PRESCRIBED BILE ACID SEQUESTRANTS 53

CHOLESTEROL ABSORPTION INHIBITORS 54

FIBRATES 54

TABLE 21 COMMONLY PRESCRIBED FIBRATES 54

NIACIN 55

COMBINATION MEDICATIONS 55

DIURETICS 55

THIAZIDE DIURETICS 56

LOOP DIURETICS 56

POTASSIUM-SPARING DIURETICS 56

TABLE 22 COMMONLY PRESCRIBED DIURETICS: BRAND NAME, GENERIC NAME, TYPE, AND MANUFACTURER 57

ERYTHROPOIESIS-STIMULATING AGENTS 58

TABLE 23 COMMONLY PRESCRIBED ERYTHROPOIESIS-STIMULATING AGENT 58

GLUCOSE MANAGEMENT 59

TABLE 24 COMMONLY PRESCRIBED GLUCOSE MANAGEMENT DRUGS 60

TABLE 24 (CONTINUED) 61

OTHER 61

TABLE 25 OTHER COMMONLY PRESCRIBED DRUGS 61

TABLE 25 (CONTINUED) 62

HORMONES 62

ACTIVE VITAMIN D 62

CALCIUM-LOWERING DRUGS 62

ADDITIONAL MEDICATIONS FOR DIALYSIS PATIENTS 63

Heparin 63

Citrate Anticoagulant 64

MEDICATIONS FOR CKD PATIENTS ON PD 64

INTRAPERITONEAL DOSING OF MEDICATIONS 64

DRUGS USED IN CONJUNCTION WITH KIDNEY TRANSPLANTATION 65

INDUCTION DRUGS 65

IMMUNOSUPPRESSANT AGENTS 66

TABLE 26 COMMONLY PRESCRIBED IMMUNOSUPPRESSANTS 67

TABLE 27 IMMUNOSUPPRESSION MAINTENANCE REGIMEN AT DISCHARGE AND 1 YEAR AFTER TRANSPLANT, 2006 68

TABLE 28 IMMUNOSUPPRESSION DRUG USE, INDUCTION DRUGS, AT DISCHARGE, AT 1 YEAR POST-TRANSPLANT, 2005 AND 2006 (%) 69

PHARMACEUTICALS USED IN ACUTE RENAL FAILURE 69

PHARMACEUTICALS USED IN CHRONIC RENAL FAILURE 70

TABLE 29 PREVALENCE OF HYPERTENSION AND DYSLIPIDEMIA BY CKD STAGE (%) 71

TABLE 30 AWARENESS, TREATMENT AND CONTROL OF HYPERTENSION, DYSLIPIDEMIA, AND DIABETES BY CKD STAGE (%) 71

TABLE 30 (CONTINUED) 72

COSTS 72

TABLE 31 COSTS OF COMMONLY USED PRESCRIPTION DRUGS FOR TREATING RENAL FAILURE AND ASSOCIATED DISEASES 73

TABLE 31 (CONTINUED) 74

THE U.S. MARKET FOR PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT 74

THE MARKET FOR MEDICATIONS TO TREAT DISEASES UNDERLYING CKD 75

THE MARKET FOR PHARMACEUTICALS USED IN ESRD TREATMENT FOR IN-CENTER DIALYSIS PATIENTS 75

CMS' New Bundled Dialysis Payment 76

THE MARKET FOR PHARMACEUTICALS USED FOR ESRD PATIENTS DIALYZING AT HOME 77

THE MARKET FOR PHARMACEUTICALS USED IN TREATING ARF 77

THE MARKET FOR PHARMACEUTICALS USED IN KIDNEY TRANSPLANTATION 78

TABLE 32 THE U.S. MARKET FOR PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT BY TYPE, THROUGH 2014 ($ MILLIONS) 79

FIGURE 14 THE U.S. MARKET FOR PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT BY TYPE, 1996-2014 ($ MILLIONS) 79

Chapter-7: RENAL RELACEMENT PRODUCTS AND THERAPIES USED IN KIDNEY FAILURE TREATMENT

HEMODIALYSIS 80

THE HEMODIALYSIS SYSTEM 80

TABLE 33 HEMODIALYSIS SYSTEM MARKET SHARE BY MAUFACTURER, 2009 (%) 81

FIGURE 15 HEMODIALYSIS SYSTEM MARKET BY MAUFACTURER, 2009 (%) 81

ACUTE CARE DIALYSIS EQUIPMENT 82

TABLE 34 THE CRRT SYSTEM MARKET BY MANUFACTURER, 2009 82

TABLE 35 DIALYSIS SYSTEMS AND MANUFACTURERS (HD, PD, CRRT) 83

DIALYZERS 83

TABLE 36 DIALYZER PRODUCTS, MANUFACTURERS, MATERIAL, AND TYPE 84

HEMOFILTERS 84

TABLE 37 HEMODIALYZERS, HEMOFILTERS MARKET SHARE, 2009 (%) 85

FIGURE 16 HEMODIALYZERS, HEMOFILTERS MARKET SHARE, 2009 (%) 85

MODES OF HEMODIALYSIS 86

Hemofiltration 86

Hemodiafiltration 86

Hemodiafiltration (Continued) 87

FIGURE 17 INTERMITTENT RENAL THERAPIES 88

MEASURING DIALYZER PERFORMANCE 89

DIALYZER REUSE 89

DIALYSATE 90

Sodium Citrate-Containing Dialysate 91

TABLE 38 DIALYSATE PRODUCTS FOR HD, PD, AND CRRT 91

TABLE 38 (CONTINUED) 92

TABLE 39 DIALYSATE MARKET BY MANUFACTURER RANK, 2009 92

DIALYSIS EQUIPMENT COSTS 92

TABLE 40 COSTS FOR COMMON DIALYSIS EQUIPMENT, HD, PD, CRRT ($) 93

THE U.S. MARKET FOR DIALYSIS SYSTEMS AND MAJOR CONSUMABLES 93

DIALYSIS MACHINES 93

TABLE 41 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, THROUGH 2014 ($ MILLION) 94

FIGURE 18 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, 1996-2014 ($ MILLION) 95

CONSUMABLES 95

TABLE 42 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, THROUGH 2014 ($ MILLION) 96

FIGURE 18 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, 1996-2014 ($ MILLION) 96

Dialyzers 96

Dialysate 97

PERITONEAL DIALYSIS 98

MODES OF PERITONEAL DIALYSIS 99

Continuous Ambulatory Peritoneal Dialysis 99

FIGURE 19 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 100

Continuous Cycler-Assisted Peritoneal Dialysis 100

Nocturnal Intermittent Peritoneal Dialysis 101

Tidal Peritoneal Dialysis 101

Dialysate for PD 102

PERITONEAL DIALYSIS EQUIPMENT MANUFACTURERS 102

TABLE 43 PERITONEAL DIALYSIS SYSTEMS, TYPE AND MANUFACTURER 102

TABLE 44 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY TYPE, 2009 (%) 103

FIGURE 20 PERITONEAL DIALYSIS EQUIPMENT MARKET BY TYPE, 2009 (%) 103

TABLE 45 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2009 (%) 104

FIGURE 21 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2009 (%) 104

CONTINUOUS RENAL REPLACEMENT THERAPIES 104

SCUF 105

CVVH 105

CVVHD 105

CVVHD (Continued) 106

FIGURE 22 CONTINUOUS RENAL THERAPIES (SCUF, CVVD, CVVHD) 107

CVVHDF 108

FIGURE 23 CONTINUOUS VENO-VENOUS HEMODIAFILTRATION 108

DIALYSIS SERVICES 109

TABLE 46 HEMODIALYSIS TREATMENT BY PROVIDER TYPE, 1990-2009 (%) 109

FIGURE 24 HEMODIALYSIS TREATMENT BY PROVIDER TYPE, 1990-2009 (%) 109

TABLE 47 U.S. DIALYSIS PROVIDERS, BY TYPE, 2008 110

TABLE 47 (CONTINUED) 111

TABLE 47 (CONTINUED) 112

TABLE 48 MARKET SHARE, HEMODIALYSIS PROVIDERS, 2009 (%) 112

FIGURE 25 MARKET SHARE, HEMODIALYSIS PROVIDERS (%) 113

THE U.S. MARKET FOR RENAL REPLACEMENT THERAPIES USED IN TREATING KIDNEY FAILURE 113

HEMODIALYSIS FOR TREATING CKD 113

Hemodialysis for Treating CKD (Continued) 114

RENAL REPLACEMENT THERAPIES FOR TREATING ARF 115

TABLE 49 THE U.S. MARKET FOR DIALYSIS THERAPY BY TYPE, THROUGH 2014 ($ MILLION) 115

FIGURE 26 THE U.S. MARKET FOR DIALYSIS THERAPY BY TYPE, 1996 TO 2014 ($ MILLION) 116

Chapter-8: SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT

VASCULAR ACCESS PROCEDURES 117

AV FISTULA 117

FIGURE 27 FOREARM AV FISTULA 118

AV GRAFT 118

FIGURE 28 A TYPE OF AV GRAFT 119

VENOUS CATHETER 119

FIGURE 29 VENOUS CATHETER 120

ACCESS REPLACEMENT/REPAIR 120

VASCULAR ACCESS MARKET BY TYPE 121

PERITONEAL DIALYSIS CATHETER 122

FIGURE 30 TENCKHOFF CATHETERS 122

PD CATHETERIZATION COSTS 122

KIDNEY TRANSPLANTATION 123

DECEASED DONORS 123

LIVING DONORS 123

THE TRANSPLANT PROCEDURE 124

Donor 124

Recipient 124

Compatibility 125

Post Surgery 125

THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN TREATING RENAL FAILURE 126

THE U.S. MARKET FOR SURGICAL ...(CONTINUED) 127

TABLE 50 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT BY TYPE, THROUGH 2014 ($ MILLION) 128

FIGURE 31 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT BY TYPE, 1996-2014 ($ MILLION) 128

Chapter-9: THE INTERNATIONAL MARKET

ESRD 129

TABLE 51 GLOBAL INCIDENCE OF END-STAGE RENAL DISEASE, 2006 (PER MILLION POPULATION) 130

TABLE 51 (CONTINUED) 131

ESRD Treatment 131

TABLE 52 GLOBAL PATIENT DISTRIBUTION BY TYPE OF DIALYSIS, 2006 (%) 132

TABLE 53 GLOBAL TRANSPLANT RATES, 2006 (PER MILLION POPULATION) 133

TABLE 53 (CONTINUED) 134

MARKET 134

MARKET (CONTINUED) 135

Chapter-10: INDUSTRY STRUCTURE

TABLE 54 LEADING PRODUCT AND THERAPY PROVIDERS FOR RENAL FAILURE TREATMENT IN THE U.S., 2009 136

PHARMACEUTICALS MANUFACTURERS 137

DIALYSIS EQUIPMENT MAKERS 137

MANUFACTURERS OF DIALYSIS CONSUMABLES 138

THERAPIES 139

DIALYSIS 139

SURGERY 140

UNOS/OPTN 140

COMPANY PROFILES 141

ABBOTT LABORATORIES 141

AMAG PHARMACEUTICALS 141

AMERICAN REGENT INC. 142

AMERICAN RENAL ASSOCIATES, INC. (ARA) 143

AMERICAN VASCULAR DIALYSIS ACCESS CENTERS 143

AMGEN 143

ASAHI KASEI KURARAY MEDICAL CO. 144

ASTELLAS PHARMA U.S., INC. 145

ASTRAZENECA PLC 145

B.BRAUN MEDICAL INC. 146

BARD ACCESS SYSTEMS, INC. 146

BAYER HEALTHCARE 147

BAXTER INTERNATIONAL 147

BIOVAIL CORP. 148

BOEHRINGER INGELHEIM 149

BRISTOL MYERS SQUIBB COMPANY 149

CANTEL MEDICAL 150

CENTERS FOR DIALYSIS CARE 151

DAVITA, INC. 151

DIALYSIS CLINIC, INC. (DCI) 151

DIALYSIS CORP. OF AMERICA (DCA) 152

DIVERSIFIED SPECIALTY INSTITUTES (DSI) 152

ELI LILLY AND CO. 153

FOREST PHARMACEUTICALS 153

FRESENIUS GROUP 153

Fresenius Group (Continued) 154

Renal Solutions, Inc. 155

GAMBRO AB 155

GENENTECH INC. 156

GENZYME CORP. 156

GLAXOSMITHKLINE PLC 157

GREENFIELD HEALTH SYSTEMS 157

INNOVATIVE DIALYSIS SYSTEMS INC. (IDS) 158

JOHNSON & JOHNSON 158

KING PHARMACEUTICALS 159

KIDNEY CENTER, INC. 159

LIBERTY DIALYSIS 160

MAQUET CARDIOVASCULAR 160

MEDCOMP 161

MEDIGROUP INC. 161

MEDICINES CO. (THE) 162

MERCK & CO. 162

MYLAN BERTEK PHARMACEUTICALS 163

NAVILYST MEDICAL 163

NIPRO CORP. 164

NORTHWEST KIDNEY CENTERS 164

NOVARTIS PHARMACEUTICALS 165

NOVO NORDISK A/S 165

NXSTAGE MEDICAL 166

PAR PHARMACEUTICAL INC. 166

PFIZER 167

PROMETHEUS LABORATORIES INC. 167

REGIONAL RENAL RESEARCH INSTITUTE (RRI) 168

RENAL ADVANTAGE, INC. 169

RENAL VENTURES MANAGEMENT LLC 169

ROCHE (F. HOFFMANN-LA ROCHE LTD.) 170

ROCKWELL MEDICAL TECHNOLOGIES 170

SANOFI-AVENTIS 171

SATELLITE HEALTHCARE/WELLBOUND 171

SHIRE PHARMACEUTICALS GROUP 172

SIGMA-TAU PHARMACEUTICALS 172

SOLVAY PHARMACETICALS, INC. 173

TAKEDA PHARMACEUTICALS 173

TERUMO CORP. 174

TEVA PHARMACEUTICALS USA 174

TORAY INDUSTRIES, INC. 175

TRANSVIVO 175

U.S. RENAL CARE, INC. (USRC) 176

VASCULAR ACCESS CENTERS 177

WAKE FOREST UNIVERSITY OUTPATIENT DIALYSIS 177

WATSON PHARMACEUTICALS 178

WYETH 178

XCORPOREAL, INC. 179

APPENDIX 180

TABLE 55 TOP 50 U.S. HOSPITALS FOR RENAL DISORDERS 180

TABLE 55 (CONTINUED) 181

TABLE 56 U.S. KIDNEY TRANSPLANT CENTERS, 2006 181

TABLE 56 (CONTINUED) 182

TABLE 56 (CONTINUED) 183

TABLE 56 (CONTINUED) 184

TABLE 56 (CONTINUED) 185

TABLE 56 (CONTINUED) 186

TABLE 56 (CONTINUED) 187

To order this report:

Therapy Industry: Renal Disease Treatments: Products and Therapies

More Market Research Report


Nicolas Bombourg
Reportlinker
Email:
 nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Reportlinker Adds Kinase Inhibitors: Global Markets
2. Reportlinker Adds Point of Care Diagnostics
3. Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets
4. Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015
5. Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
6. Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment
7. Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
8. Reportlinker Adds Peptic Ulcer Testing - A World Market Intelligence Report
9. Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks
10. Reportlinker Adds The Future of Senior Nutrition: Key Ingredients, Strategic Issues and Targeted Opportunities for Older Consumers
11. Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology: